Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21113999 | 0.96 | KDM4E (0.44) | KDM4ESMN1; SMN2ALDH1A1MAPTKMT2A | |
| SCHEMBL21113938 | 0.95 | KDM4E (0.39) | KDM4ESMN1; SMN2ALDH1A1PDK2LTA4H | |
| SCHEMBL21114092 | 0.94 | KDM4E (0.40) | KDM4ESMN1; SMN2ALDH1A1PDK2KMT2A | |
| SCHEMBL21114079 | 0.92 | KDM4E (0.38) | KDM4ESMN1; SMN2ALDH1A1PDK2MAPT | |
| SCHEMBL2719231 | 0.87 | KDM4E (0.45) | KDM4ESMN1; SMN2ALDH1A1PDK2MAPT | |
| SCHEMBL21163146 | 0.86 | PDK2 (0.46) | KDM4ESMN1; SMN2ALDH1A1PDK2TDP1 | |
| SCHEMBL21114117 | 0.83 | PDK2 (0.45) | KDM4ESMN1; SMN2PDK2KMT2ATDP1 | |
| SCHEMBL21113990 | 0.83 | PDK2 (0.44) | KDM4ESMN1; SMN2PDK2L3MBTL1KMT2A | |
| SCHEMBL21114115 | 0.83 | CXCR2 (0.30) | — | |
| SCHEMBL21114178 | 0.83 | PDK2 (0.44) | KDM4ESMN1; SMN2PDK2L3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190210973-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2019-07-11 | — | — | US | disclosed |
| WO-2019136314-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2019-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190210973-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC26A4, SERPINB1 | KDM4E 4784/4885SMN1; SMN2 3380/4885ALDH1A1 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.